For patients under 65, GLP-1 access is largely a commercial-insurance and employer question. For Medicare beneficiaries, it is a different story entirely. Statute, CMS policy, and Part D plan design have combined to make GLP-1 coverage patchy, condition-dependent, and in flux. This post walks through the current state heading into 2026: which indications are covered, which are not, what the Treat and Reduce Obesity Act (TROA) would change, and how Medicare drug-price negotiation affects semaglutide.
Key Takeaways
- Medicare Part D cannot cover weight-loss drugs by statute. Section 1860D-2(e)(2)(A) excludes drugs used for anorexia, weight loss, or weight gain.
- GLP-1s with a non-obesity indication are covered. Semaglutide (Ozempic) for type 2 diabetes; semaglutide (Wegovy) for cardiovascular risk reduction in overweight/obese patients with established CVD.
- March 2024 CMS clarification: Wegovy for cardiovascular risk reduction (post-SELECT) is coverable under Part D — a workaround within the statute.
- TROA (Treat and Reduce Obesity Act) would amend the statute to allow Part D coverage of obesity drugs directly. It has bipartisan support but has not passed.
- Semaglutide is in the first wave of Medicare drug-price negotiation under the IRA. Negotiated prices take effect January 1, 2027.
- Practical access today: Medicare beneficiaries can often access GLP-1s via diabetes diagnosis, cardiovascular diagnosis (Wegovy + prior CV event), or by paying cash.
Why Medicare Doesn't Cover Obesity Drugs
The Medicare Part D statute was written in 2003 and explicitly excludes several drug categories from Part D coverage. One of those categories is "drugs when used for anorexia, weight loss, or weight gain." At the time, the legislative concern was fen-phen-era weight-loss drugs with safety problems. The exclusion has outlasted the drugs that motivated it.
The practical effect: a Medicare beneficiary with obesity but no diabetes and no cardiovascular disease could not obtain Wegovy or Zepbound through Medicare for weight loss alone — even though their clinical case for the therapy would be identical to that of a 50-year-old with employer coverage.
The Cardiovascular Workaround
In March 2024, CMS clarified that if a Part D drug has an additional medically accepted indication beyond weight loss, Part D plans could cover it for that other indication. The timing was not accidental. Semaglutide's SELECT trial had shown that Wegovy reduces major adverse cardiovascular events by 20% in overweight/obese adults with established cardiovascular disease. In March 2024, FDA added cardiovascular risk reduction as an approved indication for Wegovy.
The result: a Medicare beneficiary with obesity and a prior heart attack, stroke, or symptomatic CVD can access Wegovy through Part D for cardiovascular risk reduction, with weight loss as a biological consequence. For obesity without CVD, no coverage.
What About Zepbound (Tirzepatide)?
Zepbound has an obesity indication only — no cardiovascular indication yet. SURMOUNT-MMO (the cardiovascular outcomes trial) will determine whether tirzepatide joins semaglutide in the CV-indicated-therefore-Part-D-coverable club. Readouts are expected across 2026–2027. Until then, Zepbound coverage via Medicare is extremely limited.
Mounjaro (same molecule, same manufacturer, tirzepatide branded for type 2 diabetes) is covered when used for its diabetes indication, as a Part D-covered diabetes drug.
Treat and Reduce Obesity Act (TROA)
TROA is a legislative proposal, re-introduced in successive Congresses, that would amend the Part D statute to allow coverage of obesity drugs for the indication of obesity treatment. It has bipartisan support and has repeatedly been scored by CBO. The core question has always been cost — a cost estimate that has moved substantially as GLP-1 drugs have become more effective and more expensive.
As of 2026, TROA has not passed. The policy environment remains fluid: CMS has broader authority to interpret the statute than it has historically used, and Congress has periodically bundled TROA-adjacent provisions into larger drug-pricing legislation.
Medicare Drug-Price Negotiation and Semaglutide
The Inflation Reduction Act of 2022 created a Medicare drug-price negotiation program. The first ten drugs went through negotiation for 2026 pricing. Semaglutide (Ozempic/Wegovy) was selected for the second wave of negotiation, with negotiated prices taking effect January 1, 2027.
Three implications for Medicare patients and the broader obesity market:
- Significantly lower Medicare price for semaglutide starting 2027 — likely 40–60% below current list price based on first-wave outcomes.
- Pressure on commercial payers to approach negotiated levels, though commercial pricing is contractually separate.
- Spillover to tirzepatide: once semaglutide's Medicare price drops, tirzepatide's premium becomes a sharper negotiation issue for payers.
What Medicare Beneficiaries Can Do Today
Four practical paths for Medicare patients seeking GLP-1 therapy:
- Type 2 diabetes diagnosis. Ozempic, Mounjaro, Rybelsus, and other GLP-1 diabetes drugs are Part D-covered. Many patients meet diabetes criteria without realising it.
- Established CVD + obesity. Wegovy for cardiovascular risk reduction is Part D-covered. Requires prior MI, stroke, or symptomatic peripheral arterial disease.
- Manufacturer patient-support programs. Lilly and Novo offer direct-pay programs below branded retail pricing. Lilly's LillyDirect has sold Zepbound vials direct-to-consumer at reduced cash prices.
- Compounded alternatives (with major caveats). The FDA 503B bulks list for semaglutide and tirzepatide has substantially restricted compounded supply as of 2026. Previously available compounding routes have narrowed. See our prior coverage of the 503B exclusion for the regulatory background.
What Clinicians Should Know
Three documentation points matter in 2026:
- Code to the CV indication where appropriate. Wegovy for post-MI/post-stroke patients is coverable; coding this as obesity treatment will trigger denials.
- Document diabetes carefully. Semaglutide for diabetes requires the diabetes diagnosis in the Part D claim. Off-label obesity use masquerading as diabetes is a compliance risk.
- Track plan formulary tiering. Even covered GLP-1s are often placed in high-tier Part D formulary slots with substantial patient cost-sharing. Patient out-of-pocket is often the practical barrier even when coverage technically exists.
The 2027 Horizon
Three events will reshape Medicare GLP-1 access in 2027:
- Negotiated semaglutide price takes effect January 1, 2027
- Zepbound CV outcomes (SURMOUNT-MMO) may enable CV-indication Part D coverage
- Any TROA progress or CMS reinterpretation could broaden obesity-indication coverage
Any one of these would expand access substantially. The combination would materially change the Medicare obesity-treatment landscape.
Frequently Asked Questions
Can Medicare cover Wegovy or Zepbound for obesity alone?
No. The Part D statute explicitly excludes drugs used for weight loss. Coverage requires an additional covered indication (type 2 diabetes, cardiovascular risk reduction, etc.).
Does Medicare cover Wegovy at all?
Yes — but only for cardiovascular risk reduction in overweight/obese adults with established cardiovascular disease. Not for obesity treatment alone.
What about Medicare Advantage plans?
Medicare Advantage plans deliver Part D benefits and are bound by the same statutory exclusion. Some MA plans offer limited supplemental benefits, but these do not include obesity drug coverage at any scale.
Will Medicare pay less for GLP-1s under drug-price negotiation?
Yes, for semaglutide starting January 1, 2027. The negotiated maximum fair price has not yet been published but will substantially reduce Medicare's and beneficiaries' costs. Tirzepatide is not in the second wave but could appear in later waves.
What should a patient on Medicare do if they want a GLP-1 for weight loss?
Discuss with a clinician whether any covered indication applies (type 2 diabetes, established CVD, obesity-related CVD). If not, review manufacturer direct-pay programs or self-pay options. Compounded routes have narrowed considerably since the 2026 FDA 503B rulings.
Is TROA likely to pass soon?
Unclear. It has bipartisan support but faces cost scoring and competing legislative priorities. The negotiated semaglutide price taking effect in 2027 may reduce fiscal objections.
Primary sources:
- CMS — Medicare Drug Price Negotiation Program
- CMS — Part D Guidance on Covered Indications
- Treat and Reduce Obesity Act — Congress.gov
- SELECT Trial — Semaglutide and Cardiovascular Outcomes (NEJM 2023)
Research disclaimer: This article summarises publicly available policy information for educational purposes. It is not legal, financial, or medical advice. Medicare rules change frequently; verify current coverage with CMS, your plan, or a licensed advisor.
